Cerulean Appoints Vice President, Regulatory Affairs

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Cerulean Appoints Vice President, Regulatory Affairs

CAMBRIDGE, Mass., Oct. 6, 2014 (GLOBE NEWSWIRE) -- Cerulean Pharma Inc. (Nasdaq: CERU ), a leader in Dynamic Tumor Targeting™, today announced the appointment of Pamela Strode as Vice President, Regulatory Affairs.

"Pam has extensive regulatory and oncology experience across all phases of product development, from pre-clinical through the post marketing life-cycle, as well as strategic expertise that will help Cerulean advance its nanoparticle-drug conjugates, or NDCs, through the clinic to commercialization," said Oliver Fetzer, Ph.D., President and Chief Executive Officer of Cerulean.

Strode will oversee all facets of Cerulean's regulatory affairs, providing oversight for all U.S. and international regulatory matters, including filings and interactions with regulatory authorities.

Ms. Strode joins Cerulean from Boehringer Ingelheim Pharmaceuticals, Inc., where she spent approximately 20 years in positions of increasing responsibility in drug regulatory affairs, most recently as Executive Director. Prior to Boehringer Ingelheim, Ms. Strode worked in regulatory affairs for 6 years at Bristol-Myers Squibb and previously worked in research and development there and at Hoffmann-La Roche. Ms. Strode received a B.S. in Microbiology from Cook College at Rutgers University and a M.S. in Quality Assurance and Regulatory Affairs from Temple University.

"Cerulean's NDCs are intriguing to me because they are designed to specifically target tumor cells, spare normal tissue, and most importantly to enable unique combinations," said Ms. Strode. "My new role provides an opportunity to immediately leverage my experience to help advance the three combination trials evaluating CRLX-101 and to help usher CRLX-301 into the clinic."

About Cerulean Pharma

The Cerulean team is committed to improving treatment for people living with cancer. We apply our Dynamic Tumor Targeting Platform to create a portfolio of nanoparticle-drug conjugates, or NDCs, designed to selectively attack tumor cells, reduce toxicity by sparing the body's normal cells, and enable therapeutic combinations. Our lead product candidate, CRLX101, is in multiple clinical trials with other cancer treatments, all of which aim to unlock the power of combination therapy. For more information, please visit www.ceruleanrx.com .

Cautionary Note on Forward Looking Statements

Any statements in this press release about our future expectations, plans and prospects, including statements about the clinical development of our product candidates, and other statements containing the words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "would," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation of clinical trials, availability and timing of data from ongoing and future clinical trials and the results of such trials, whether preliminary results from a clinical trial will be predictive of the final results of that trial or whether results of early clinical trials will be indicative of the results of later clinical trials, expectations for regulatory approvals, availability of funding sufficient for our foreseeable and unforeseeable operating expenses and capital expenditure requirements and other factors discussed in the "Risk Factors" section of our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 12, 2014 and in other filings that we make with the Securities and Exchange Commission. In addition, any forward-looking statements included in this press release represent our views only as of the date of this release and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligation to update any forward-looking statements included in this press release.

Aurora Krause Cerulean Pharma Inc. Corporate Communications 617-551-9627

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Vipshop Prepares for Q3 Financial Results Release

Updated Category News Views 60

Countdown to Vipshop's Third Quarter Results November 24th might just be another day on the calendar for some, but for those of us keeping tabs on the markets, it's a make-or-break moment for Vipshop Holdings Limited. The off-price retail titan from China, trailing under the ticker NYSE:VIPS, is gearing up to swing the doors wide open on its third-quarter financial...

Continue Reading
Orangetheory Adds NASM Training for Coaching Edge

Updated Category News Views 19

A Shift in Coaching Standards Ever seen a fitness brand tilt towards a change so fast it leaves you slack-jawed? Well, here we go with Orangetheory Fitness pushing its chips all in with NASM-certified coaches geared for the GLP-1 era. A bold move? Sure, but they aim to become trendsetters instead of just another player in the fitness game. The Impact of NASM Certification...

Continue Reading
HearUSA Expands Access with AI-Powered Hearing Aids

Updated Category News Views 24

AI Revolution in Hearing Care Look, the hearing aid industry isn't known for headlines that grab you by the throat, but HearUSA just tossed a proverbial grenade into the scene with Widex Allure AI RIC. This is more than a slight tweak in hearing tech—it's a game-changer. We're talking about on-demand AI noise management blended with Widex's renowned natural sound. It's...

Continue Reading
Akeso's Gumokimab Wins NMPA Approval for AS Treatment

Updated Category News Views 139

Gumokimab Approved: A New Dawn in AS Treatment Yeah, the biotech world shifts gears today as Akeso's gumokimab received the green light from China's National Medical Products Administration (NMPA). This approval for treating ankylosing spondylitis, or AS, isn't just another checkbox for Akeso; it's a game-changer in tackling this chronic inflammatory disease. Why should...

Continue Reading
YYForce's Strategic Play: Robotics and AI Expansion

Updated Category News Views 11

Innovation Meets Pragmatism at YYForce There's a new bout of excitement brewing over at YYForce Inc. (NASDAQ: YFOR), if the latest announcements are anything to go by. The Singapore-based AI-enabled workforce dynamo is laying out priorities like a general plotting a campaign—pragmatic, strategic, and with a keen eye on the bottom line. Aiming for a Technological Edge In...

Continue Reading
Flagship's £100M London Move to Ignite AI Ventures

Updated Category News Views 150

London Calling: Flagship's New Venture Flagship Pioneering, the brain behind bustling biotech ventures like Moderna, is planting its flag in London. They're launching Flagship Origination Lab, U.K., their first real gig outside good ol' Cambridge, Massachusetts. They're diving in headfirst, sprinkling a whopping £100 million to brew up AI-native platform companies. And...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 254

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
CureGene's CG-0416: Promising Weight Loss Breakthrough

Updated Category News Views 94

Game-Changer in Weight Management? Oh, the obesity world is buzzing, folks! There's some big noise coming from CureGene, and it's catching the attention of every lab-coat smarty in town. They just tossed out some preclinical data on CG-0416 at Obesity Week 2026 that could shake up how we tackle weight loss. Anyone still clinging to their old diet books might want to take...

Continue Reading
Asia-Pacific Miracle: New Economic Chapter Unfolds

Updated Category News Views 31

A Fresh Breeze in Asia-Pacific's Sails You ever look around and realize everything's about to change—again? That's Asia-Pacific right now. We're staring down the barrel of a new chapter in what folks are calling the "Asia-Pacific miracle." The text from China Daily paints a picture of a region gearing up to crank the cooperation dial even higher. And where's this...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 343

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading

Top 5 Most Recently Viewed Articles

BitGo Faces Securities Fraud Suit Amid Investor Losses

Updated Category News Views 69

BitGo's Legal Woes: A Deep Dive into the Allegations A lawsuit can shake up a company's foundations, and BitGo Holdings, Inc. (NYSE: BTGO) is feeling the heat right now. The focus of this busy investor morning isn’t some penny stock drama; we're talking about players in the digital asset game accused of pulling the wool over investors' eyes. Slap on those reading...

Continue Reading
Investors Alert: Deadline Approaches in Match Group Lawsuit

Updated Category News Views 141

Important Deadline Approaching for Match Group Investors Recently, there has been a notable reminder for investors concerning a class action lawsuit involving Match Group, Inc. (NASDAQ: MTCH). The law firm Glancy Prongay & Murray LLP has highlighted that all individuals who purchased shares in Match Group during the specified period should be aware of the upcoming...

Continue Reading
Leadership Transition at Coloplast A/S: New Era Begins

Updated Category News Views 937

Coloplast A/S Announces Leadership Change In a significant shift for Coloplast A/S, CEO Kristian Villumsen has officially stepped down. Today marks the start of a new chapter as the Board of Directors mobilizes Lars Rasmussen to serve as interim CEO while the search for a permanent replacement is conducted. Strategic Shift for the Future This change comes at an opportune...

Continue Reading
Johnson & Johnson's Strong Q3 Results Amid Market Declines

Updated Category News Views 109

Market Overview On a day marked by declining values, U.S. stocks experienced a noticeable downturn. The Nasdaq Composite index saw a drop of around 150 points, indicating a challenging market environment. As trading progressed, the Dow Jones Industrial Average slipped slightly, and the S&P 500 also followed suit, showing varied performance across sectors. Sector...

Continue Reading
Moroccanoil Expands Product Line at Ulta Beauty Nationwide

Updated Category News Views 204

Moroccanoil Expands Product Line at Ulta Beauty Nationwide Moroccanoil is thrilled to announce an exciting partnership with Ulta Beauty, the premier beauty retailer in the nation. This significant expansion reaffirms Moroccanoil's commitment to delivering high-quality beauty products to a wider audience while honoring its legacy rooted in the salon community. Launching at...

Continue Reading